SCHEMBL10122970

SCHEMBL10122970

CN1CCN(c2cc(Nc3cc(O)[nH]n3)nc(/C=C/c3ccccc3)n2)CC1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 15/20 0.80
AURKB Q96GD4 5/20 0.80
NTRK1 P04629 5/20 0.80
KDR P35968 3/20 0.80
FLT3 P36888 3/20 0.80
PLK4 O00444 2/20 0.80
ABL1 P00519 2/20 0.80
LCK P06239 2/20 0.80
CSF1R P07333 2/20 0.80
RET P07949 2/20 0.80
KIT P10721 2/20 0.80
FGFR1 P11362 2/20 0.80
SRC P12931 2/20 0.80
PDGFRA P16234 2/20 0.80
TYK2 P29597 2/20 0.80
PTK2 Q05397 2/20 0.80
MAP4K5 Q9Y4K4 2/20 0.80
FGFR3 P22607 2/20 0.80
CHEK1 O14757 1/20 0.80
PDPK1 O15530 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enmd-2076 SCHEMBL15668060 0.89 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL29355178 0.89 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL10122872 0.89 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL10122873 0.89 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
SCHEMBL10122969 0.86 AURKA (0.77) AURKAAURKBNTRK1KDRFLT3
SCHEMBL10122967 0.85 AURKA (0.76) AURKAAURKBNTRK1KDRFLT3
SCHEMBL10122878 0.84 AURKA (0.73) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL15239834 0.84 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL29379147 0.84 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3
Enmd-2076 SCHEMBL29381911 0.84 AURKA (1.00) AURKAAURKBNTRK1KDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928456-B1 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS INC (US) 2015-04-22 EP disclosed
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-8114870-B2 Method of treating disease states using substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2012-02-14 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. 2009-10-22 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-7563787-B2 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. (US) 2009-07-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
WO-2007041358-A2 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142368-A1 Substituted pyrazole compounds AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885NTRK1 2241/4885
US-20090264422-A1 METHOD OF TREATING DISEASE STATES USING SUBSTITUTED PYRAZOLE COMPOUNDS AURKC, AURKA, AURKB AURKA 2/4885AURKB 3/4885NTRK1 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.